Oncology Central

With the Global Menopause and Cancer Conference 2026 (18 September 2026, London, UK) fast approaching, we're delighted to share a sneak peek of what the conference will cover. The program will feature...

Transcript I'm Emma Hall, Editor at Oncology Central and today I'm joined by Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School (MA, USA).

Minimally invasive laser therapy has been shown to extend survival when more tumor is removed and treatment occurs earlier, offering a less invasive alternative to traditional open-skull surgery. For patients facing a diagnosis of glioblastoma - one of the most aggressive and devastating forms of brain cancer - the standard path forward has long meant an...

DNA sequencing of newborn blood samples could identify approximately 7% of children who later developed cancer by age eight. A large population-based study led by researchers at Mass General Brigham and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center suggests that genetic testing added to routine newborn screening could identify some babi...

177Lu-PSMA-617 added to standard therapy reduces disease progression risk by 28% in PSMA-positive metastatic prostate cancer patients when administered at diagnosis. An international team of researchers has reported positive results on the early use of targeted radiopharmaceutical therapy for patients with newly diagnosed PSMA-positive metastatic prostat...